GilR is a recently identified oxidoreductase that catalyzes the terminal step of gilvocarcin V biosynthesis and is a unique enzyme that establishes the lactone core of the polyketide-derived gilvocarcin chromophore. Gilvocarcin-type compounds form a small distinct family of anticancer agents that are involved in both photo-activated DNA-alkylation and histone H3 cross-linking. High resolution crystal structures of apoGilR and GilR in complex with its substrate pregilvocarcin V reveals that GilR belongs to the small group of a relatively new type of the vanillyl-alcohol oxidase flavoprotein family characterized by bicovalently tethered cofactors. GilR was found as a dimer, with the bicovalently attached FAD cofactor mediated through His-65 and Cys-125. Subsequent mutagenesis and functional assays indicate that Tyr-445 may be involved in reaction catalysis and in mediating the covalent attachment of FAD, whereas Tyr-448 serves as an essential residue initiating the catalysis by swinging away from the active site to accommodate binding of the 6R-configured substrate and consequently abstracting the proton of the hydroxyl residue of the substrate hemiacetal 6-OH group. These studies lay the groundwork for future enzyme engineering to broaden the substrate specificity of this bottleneck enzyme of the gilvocarcin biosynthetic pathway for the development of novel anti-cancer therapeutics.
are the most active, as the vinyl group is necessary for the photo[2ϩ2]cycloaddition to DNA-thymine residues (2, 9, 10) . Not so clear is the function of the glycosidic moiety, in which, interestingly, all gilvocarcin-type anticancer drugs differ from each other. The variants include d-and l-sugars, pyranoses and furanoses, amino and neutral sugars including branched sugars. In most cases, this sugar moiety is C-glycosidically linked to C-4. Because this attachment is on the opposite side of the molecules relative to the vinyl side chains and the sugars contain all the chirality of the molecules, the sugar residues are essential for the biological activity (11, 12) and likely play a crucial role for the histone H3 binding (supplemental Fig. S2 ).
The biosynthetic pathway of selected members of the gilvocarcin group was studied in our laboratory over the past 7 years, and 3 biosynthetic gene clusters (gilvocarcin V 1, ravidomycin V 4, and chrysomycin A 5, supplemental Fig. S1 ) were cloned and characterized (13, 14) . Key steps of this pathway are the oxidative rearrangement, which converts an angucyclinone intermediate into the final benzo [d] naphtho [1,2-b] pyran-6-one frame and is initiated by an oxidative 5,6-bond cleavage (15, 16) . The final dehydrogenation step is catalyzed by GilR, which converts a hemiacetal into the central lactone moiety of the polyketide-derived tetracyclic ring skeleton of the gilvocarcins ( Fig. 1) (17) . It was found that this last biosynthetic step, the conversion of pregilvocarcin V 8 to 1 ( Fig. 1 and supplemental Fig. S1 ) catalyzed by GilR, is a key bottleneck step. GilR was shown to have very narrow substrate specificity and does not tolerate alternative molecules with different sugar residues (17) . This is a major obstacle for future approaches to generate better, soluble gilvocarcin analogues with improved biological and pharmacological properties by combinatorial biosynthesis, because the variation of the sugar moiety is the most promising and most feasible strategy in this context. Therefore, it is mandatory to understand the substrate binding and conversion by GilR, which likely will offer strategies to overcome its narrow substrate specificity through enzyme engineering. As a crucial step in this direction, here we report the high resolution crystal structures of GilR in apo form and in complex with pregilvocarcin V (preGV), which gave insight into the catalytic pocket of GilR with its crucial residues Tyr-445 and Tyr-448 as well as its reaction mechanism. These studies lay the groundwork for future enzyme engineering to broaden the substrate specificity for the development of novel gilvocarcin-type anti-cancer therapeutics.
EXPERIMENTAL PROCEDURES
Cloning and Mutagenesis-GilR was cloned from cosmid G9B3 into vector pET28a(ϩ) (Novagen) as described in Kharel et al. (17) to produce pET-GilR-His 6 . Site-directed mutagenesis was performed under standard conditions with primers (supplemental Table S1 ) using the QuikChange Lightning Mutagenesis kit (Stratagene) and the pET-GilR construct as the template for all single site mutations. The H65A/C125A double mutant was constructed using H65A primers and pET-GilR-C125A vector as the template. Oligonucleotide primers were from IDT-DNA, and sequences were verified by sequencing analysis (Davis Sequencing). Restriction enzymes were from New England Biolabs and media, and other chemicals were from Fisher and Sigma.
Protein Expression and Purification-The pET-GilR-His 6 vector was transformed into BL21(DE3) cells and plated on LB agar with 50 g/ml kanamycin sulfate and grown overnight at 37°C. Colonies were picked to inoculate a 5-ml culture of LB. The culture was grown at 37°C for ϳ8 h with shaking at 250 rpm and then used to inoculate a 100-ml preculture in a 250-ml baffled flask. The preculture was grown overnight at 37°C with shaking at 250 rpm. The preculture was used to inoculate ten 100-ml cultures in 250-ml baffled flasks at 37°C with shaking at 250 rpm. The cultures were grown to an A 600 of 0.5-0.7 and then induced with 1 mM isopropyl 1-thio-␤-D-galactopyranoside. Cultures were grown overnight (ϳ16 h) with continued shaking but at a reduced temperature of 18°C and harvested by centrifugation. The cell pellet was resuspended with lysis buffer (50 mM KH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 7.6), lysed by at least two passages through a French press (Thermo Electron), and then centrifuged at 18,000 ϫ g in a Sorvall RC6ϩ centrifuge with Thermo Scientific FIBER Lite F21-8 ϫ 50y rotor for 30 min at 4°C. The supernatant was collected for further purification.
GilR-His 6 was purified by affinity chromatography using the standard IMAC-Desalting program with the Profinia protein purification system (Bio-Rad), a 1-ml Profinity IMAC cartridge (Bio-Rad), and a 5-ml Biogel P-6 desalting cartridge (Bio-Rad). GilR-His 6 protein used for activity assays was then concentrated with an Ultracel 30K centrifugal filter (Millipore) and stored as a 25% glycerol stock at Ϫ20°C. Protein concentration was determined by the Bradford assay. GilR-His 6 protein for crystal studies was further processed to remove the affinity tag. GilR-His 6 protein was treated with biotinylated thrombin enzyme (Thrombin Cleavage Capture kit, Novagen) at 4°C overnight (ϳ16 h) with gentle rocking. Thrombin was then removed by treatment with streptavidin-linked agarose beads at 4°C with gentle rocking for 30 min. The beads were then separated from the cleaved protein by centrifugation at 500 ϫ g for 5 min at room temperature with spin filters (Novagen). Free cleaved His tags and uncleaved protein were separated by passage across a 2-ml column of Talon metal affinity resin (Clon- tech) using lysis buffer. GilR was concentrated to ϳ200 l with an Ultracel 30K filter (Millipore) and further purified by gel filtration across a Superose 6 10/300 GL Tricorn high performance column (Amersham Biosciences) using a BioLogic DuoFlow FPLC system (Bio-Rad) and crystallization buffer (20 mM Tris, pH 7.5, 200 mM NaCl). Fractions were collected and concentrated to bring the total protein concentration to ϳ10 mg/ml. Protein concentration was determined by Bradford assay. 20 mg/liter wild type GilR was expressed, whereas single mutants and a double mutant expressed ϳ25 and 10% of wild type, respectively.
Crystallization and Data Collection-For the unliganded structure, GilR was concentrated to 10 mg/ml in 20 mM, Tris 7.5, and 200 mM NaCl. Broad matrix screening was performed using a TTP LabTech Mosquito crystallization robot and crystals from the initial lead conditions screened using our in-house x-ray diffractometer (Rigaku MicroMax-007 HF microfocus x-ray generator, Raxis IVϩϩ detector). Final conditions consisted of 100 mM Tris 8.5, 200 mM MgCl 2 , 20% PEG 8000, and 5-15% glycerol. Crystals typically grew to full size within 2-4 days and were harvest directly from the drop and flash-cooled in liquid nitrogen. Final datasets for the unliganded GilR structure were collected at the SER-CAT beamline at the Advanced Photon Source at Argonne National Laboratory.
For the preGV complex structure, GilR crystals were soaked with preGV at a final concentration of 5 mM in a final volume of 2 l (1 l of preGV in protein buffer and 1 l of well solution). Crystals were allowed to soak for 15-60 min before being harvested directly from the drop and flash-cooled in liquid nitrogen. Final datasets for the GilR-preGV structure were collected at the GM/CA-CAT beamline at the Advanced Photon Source at Argonne National Laboratory. All data were processed using HKL2000 (18) and statistics are summarized in Table 1 .
Structure Determination-The unliganded GilR structure was solved by molecular replacement to 1.65 Å using PHASER (19) within CCP4 (20, 21 ). An initial model was built by the Swiss-Model server (22) using PDB code 2IPI as a template. Four molecules were found in the asymmetric unit consisting of what appeared to be two dimers, with each monomer of the putative dimer related by a 2-fold symmetry axis. A difference map clearly indicated the locations of the FAD molecules within each monomer.
For the GilR-preGV complex structure, the GilR structure was used as a search model and was solved to 2.3 Å by molecular replacement. A difference map clearly revealed additional density for the preGV ligand along the predicted substrate binding site.
All model building was performed using COOT (23) , and refinement was performed using PHENIX (24) and CCP4 (20, 21) . Electrostatic surface potentials were calculated using the APBS Tools2 plugin (25) and visualized using PyMOL 1.3 (Schrödinger). All figures were prepared using PyMOL, and final editing was done in Adobe Illustrator. Root mean square deviation analysis was performed within PyMOL, and Ligplot analysis was performed using the program Ligplot (26) .
Enzyme Activity Assays-Wild type and mutant GilR enzymes were tested for activity using a modified version of the enzyme assay described in Kharel et al. (17) . For single time point assays, 120-l reactions with 100 M pregilvocarcin V, 15% DMSO, and 1 M enzyme were run for 30 s at 37°C and then quenched by the addition of 300 l of ethyl acetate. Reactions were extracted twice, then dried and re-dissolved in 100 l of acetonitrile. The reaction products were analyzed by HPLC-MS (Waters) across a C 18 column (Symmetry). Steady state parameters were determined by running large scale reactions (1.2 ml) with 15.63 nM enzyme and removing 120-l aliquots at specific time points (0, 30, 60, 120, 240, 300 s). Substrate concentration was varied from 0 to 100 M. TCA protein precipitation and FAD concentration was determined as described previously in Beam et al. (71) .
Quantitation-The area of each substrate and product peak, A i (t), at each time was determined by integration of the peaks using MassLynx software (Waters). Each area was normalized with respect to the sum of the areas in the starting substrate peaks, A 0,preGV(R) (t) and A 0,preGV(S) (t), plus the product peak, A 0,GV (t) according to Equation 1.
This normalized product fraction, F i , norm , was then corrected for background intensity at time, t ϭ 0, for the ith peak area and renormalized for background intensity of the product peak area to obtain the final corrected product fraction, F i,corr , according to Equation 2. a Statistics for the last resolution shell are shown in parentheses. b Rsym ϭ ⌺hkl,j (͉Ihkl Ϫ ͗Ihkl͉͘)/⌺hkl,j Ihkl, where ͗Ihkl͘ is the average intensity for a set of j symmetry-related reflections, and ͗Ihkl͘ is the value of the intensity for a single reflection within a set of symmetry-related reflections.
where F o is the observed structure factor amplitude, and F o is the calculated structure factor amplitude.
where a test set, T (5% of the data), is omitted from the refinement. e Performed using Procheck.
Each reaction time course was fitted to a single exponential curve outlined in Equation 3 where A is the amplitude, and k app is the apparent rate constant.
Nonlinear least squares fittings were performed using Kaleidagraph software (Synergy).
Light Scattering-A 200-l sample of native GilR (2.25 mg/ml) was centrifuged for 15 min (4°C) at 60,000 rpm using a TLA 120.1 rotor in an Optima MAX ultracentrifuge and then passed though a 0.2 M filter. This sample was then loaded into an Agilent Technologies 1200 Series Quaternary HPLC instrument equipped with a Shodex KW-803 gel filtration column (50 -150,000 M r range), which was in-line to a Wyatt Dawn Heleos multiangle light scattering detection instrument and a Wyatt Optilab T-rEX refractive index detection instrument. The sample was eluted at 0.3 ml/min for 60 min in 1ϫ PBS and monitored using the Wyatt Astra software. BSA was used as a standard (data not shown).
Analytical Ultracentrifugation-All experiments were conducted at 20°C with a Beckman Optima XL-A analytical ultracentrifuge (Beckman, Palo Alto, CA) equipped with a four-hole An60Ti rotor and cells with 12-mm double-sector Epon centerpieces and quartz windows. GilR was dialyzed overnight in 1ϫ PBS (K D Medical). For sedimentation velocity experiments, 0.4 ml sample volumes were used. Centrifuge rotor was accelerated to 50,000 rpm after thermal equilibrium was reached at rest. Absorbance scans at 280 or 230 nm were started immediately after the rotor reached the set speed and collected continuously until no further sedimentation boundary movement was observed. Partial specific volume of GilR, buffer density, and viscosity were calculated using the SEDNTERP program (27) . Data analysis was conducted using the c(s) method in the SEDFIT program (28) . The same software was used to calculate weight average sedimentation coefficients from distributions and to correct the sedimentation coefficients to standard conditions, s 20 , w . Menisci positions and frictional ratios were optimized during the fitting procedure. All final accepted fits had S.D. of less than 0.006 units. For sedimentation equilibrium experiments, all protein concentrations of 0.18-ml sample volumes were used. After the rotor was accelerated to 8000 rpm, absorption scans of all cells were taken every 4 h and compared using WINMATCH program until equilibrium was attained. After obtaining equilibrium distributions at 8,000 rpm, the rotor was accelerated to 12,000 rpm, and the identical procedure was repeated. Global analysis was conducted using the SEDPHAT program (28) . Root mean square deviation of the final fit of the single species model to all six data sets was 0.005 units.
RESULTS
The Structure of GilR-The GilR crystal structure was solved to 1.65 Å resolution using molecular replacement based on the AknOx structure (29) . A root mean square deviation of 1.17 Å was calculated between GilR and AknOx (PDB code 2IPI), indicating the structural conservation between the two enzymes. The GilR structure (residues 6 -498) consists of an N-domain (residues 6 -220) and a C-domain (221-498) and is a mix of ␣-helices and ␤-sheets ( Fig. 2A) . The N-domain contains two ␣ ϩ ␤-folds, one containing a four-stranded ␤ sheet (␤1-␤4) sandwiched by two ␣-helices (␣1-␣2) and the other containing a five-stranded anti-parallel ␤ sheet (␤5-␤9) flanked by four ␣ helices (␣3, ␣4, ␣5, ␣13). The C-domain consists of a large seven-stranded anti-parallel ␤ sheet (␤10-␤16) flanked by four ␣helices (␣6, ␣7, ␣9, ␣10) on the outside and one helix (␣8) on the inside. The remainder of the C-domain consists of two short ␣ helices (␣11-␣12) and a longer helix (␣13) that was found nested along helix ␣5 of the N-domain. An electrostatic surface potential map shows the GilR surface to be highly electronegative with the only regions of electropositive charge found along the FAD/substrate binding site (at the interface between the N-domain and the C-domain) and along helices ␣3 and ␣8 (Fig. 2C) .
Similar to what was observed with AknOx, GilR was found as a putative dimer in our structure with each monomer related by a 2-fold symmetry axis and burying a surface area of ϳ1700 Å 2 ( Fig. 3A) . The buried surface area along the dimer interface consisted of ϳ9% of the total surface area and involved 44 residues total with Arg-16, Glu-19, Lys-110, Arg-114, Arg-115, Lys-227, Arg-313, Gly-314, Ser-318, Leu-320, Thr-321, Arg-324, Tyr-325, Ser-327, Asp-330, Cys-331, Gly-332, Asp-333, and GTln-408 involved in hydrogen bonding and Glu-19, Lys-110, Lys-227, Arg-313, Arg-324, Asp-330, and Asp-333 participating in salt bridges (PISA server) (30, 31) . The formation of the dimer creates a somewhat constricted entrance that substrate must share to access the active site of each monomer. It is currently unknown if the dimer state is required for catalysis or if a monomer state would retain any activity. Studies are currently in progress. To verify the dimeric structure of GilR, light scattering experiments were performed that showed GilR as a single peak with a mass corresponding to a dimer, and no monomer peak was observed (supplemental Fig S3) . Analytical ultracentrifugation experiments were conducted to conclusively determine whether the solution state of the enzyme is truly dimeric. Here, sedimentation velocity experiments were conducted at the protein concentration of 16, 2.7, 1.1, and 0.22 M. Representative results obtained with 1.1 M of GilR are shown in Fig. 3B . For all concentrations studied c(s) sedimentation coefficient distributions contained a single peak with an average s 20,w of 6.73 Ϯ 0.13 S, corresponding to a species with a calculated molecular mass of 108.3 Ϯ 3.3 kDa and representing the GilR dimer. Even at the lowest concentration used in this study we could not detect a peak corresponding to GilR monomer or a shift of c(s) peak to lower s values. From these data the dimerization constant of GilR can be estimated as K D Յ 100 nM. To confirm that the single species observed in sedimentation velocity experiments was a GilR dimer, we conducted the sedimentation equilibrium experiment (supplemental Fig. S4 ). Global analysis of six data sets obtained with three protein concentrations and two centrifuge speeds shows that the data can be well described by a single species model with a calculated molecular mass of 109.0 kDa. This value is in good agreement with the sequence calculated GilR molecular mass of 108.6 kDa.
The FAD Binding Site-The FAD cofactor was found to bind covalently to GilR at two distinct sites involving residues His-65 (linked to C8␣ of FAD) and Cys-125 (linked to C6 of FAD) (Figs. 2A and 4A and supplemental Fig. S5A ). The FAD binding site sits tucked primarily within the N-domain along helix ␣4 with the isoalloxazine moiety resting at the interface between the N-domain and C-domain (Figs. 4A and 5A) . Aside from the bicovalent attachment, FAD interacts with GilR through a number of hydrogen bonding and van der Waals interactions running the entire length of the molecule (supplemental Fig.  S5A ). Two residues that sit closest to the isoalloxazine ring include Tyr-139 and Tyr-445 and, thus, may play a role in the catalytic mechanism of GilR. N447 interacts with FAD along the ribitol region of FAD, and several other residues associate through the phosphate groups distal to the isoalloxazine ring. Likely, each of these interactions is necessary for the stabilization of FAD in this binding pocket.
To our knowledge, GilR represents only the fourth (others are AknOx/glucose oxidase/berberine bridging enzyme) example in crystallography describing the bicovalent attachment of FAD to an enzyme (29, (32) (33) (34) . In bicovalently linked flavoenzymes, accessibility to the FAD binding pocket is increased significantly from enzymes with only a single covalent linkage. From the crystal structure of GilR, it is evident that this enzyme also contains an open FAD binding pocket, consistent with the previous trend.
The GilR-PreGV Complex Structure-To further investigate the catalytic mechanism of GilR, we used crystal soaking experiments to determine the complexed structure of GilR with the substrate preGV. The GilR-preGV complex structure was solved to a resolution of 2.3 Å using molecular replacement, and a difference map revealed additional electron density at the catalytic site corresponding to the preGV substrate that was modeled and refined (Fig. 2B) . The preGV substrate was observed to bind in close proximity to the isoalloxazine moiety of FAD in an aromatic stacking fashion within the substrate binding cavity and sandwiched along the interface of the N-domain and C-domain (Figs. 4B and 5B). GilR interacts with the preGV substrate via a host of van der Waals interactions along the seven-stranded ␤ sheet of the C-domain and hydrogen FIGURE 2. A, the structure of GilR is shown in ribbon with ␣-helices in gold, ␤-strands in green, and loops in gray. FAD is shown in ball and stick representation, and ␣-helices are labeled in red. B, the structure of GilR in complex with preGV show GilR in ribbon with ␣-helices in gold, ␤-strands in green, and loops in gray. FAD and preGV is shown in ball and stick representation, and ␤-strands are labeled in red. C, an electrostatic surface potential representation of GilR contoured from Ϫ4kT to ϩ4kT (APBS Tools2 plugin). The red highlight indicates regions of negative electrostatic potential, and blue indicates regions of positive electrostatic potential.
bonding interactions from Ser-341, Ser-402, and Tyr-445 of the C-domain and from Tyr-139 of the N-domain. A Ligplot analysis of the preGV ligand (supplemental Fig. S5B ) best illustrates the vast number of van der Waals interactions involved in substrate binding.
An alignment of the unliganded and preGV-bound GilR structures shows no change in overall tertiary structure. Looking specifically at the residues along the active site, no significant conformational changes were observed except for Tyr-448, which swings ϳ75°(or ϳ3.0 Å along -OH group) away from the active site to accommodate binding of the preGV substrate, where it then participates in a strong hydrogen bond (2.08 Å) with the C6 hydroxyl of the hemiacetal of the substrate (Fig. 5C ). It is thought that along with Tyr-448, Tyr-139 and Tyr-445 also participate in the catalytic mechanism of GilR for the conversion of preGV to GV (Fig. 5D ). It appears that Asn-376 (ϳ3 Å distance) or Lys-400 (ϳ4 Å distance) might be best positioned to act as the base for the proposed mechanism.
Mutagenesis, FAD Binding, and Kinetics of GilR-In previous studies with AknOx, three tyrosine residues were shown to play a role in the two-step enzymatic mechanism that converts AclN to AclY (29) . The GilR structure also revealed three tyrosine residues in the active site near the substrate and FAD interface. A series of Tyr to Phe mutants (Y139F, Y445F, Y448F) was introduced to test the role of each tyrosine residue in the GilR mechanism. Additionally, three residues were interrogated to better understand the mechanism of FAD binding. H65A, C125A, a double mutant H65A/C125A, and N447A were each introduced to assay the effect of nearby residues on the ability of GilR to maintain covalent binding to FAD and proper enzyme folding and function. Initial activity assays were conducted with wild type GilR and each of the mutants (Fig. 6) .
After purification of wild type GilR and each of the mutants, the purified protein remained bright yellow, including the double mutant in which both of the residues involved in covalent FAD binding were modified. This result suggests that the double mutant binds FAD non-covalently. To test this hypothesis, each protein was precipitated by incubation with TCA and separated by centrifugation, and the supernatant was tested for FAD content (supplemental Fig. S6 ). If FAD is covalently bound to the protein, none of it should reside in the supernatant; however, if FAD is non-covalently bound, some of it will remain in the supernatant, whereas all of the enzyme will be collected in the pellet. As expected, no FAD was found in the supernatant upon precipitation of wild type GilR, whereas the double mutant (H65A/C125A) supernatant contained abundant FAD. In the supernatant of most of the single mutant samples, little to no FAD was found after precipitation. Surprisingly, the supernatant of the Y445F mutant also contained abundant FAD after precipitation.
Steady state kinetic parameters were determined through turnover assays with the wild type GilR and with each mutant enzyme along with the natural substrate preGV. For wild type GilR, a K m of 7.43 M and a k cat of 2.57 s Ϫ1 was calculated with an overall k cat /K m of 346 s Ϫ1 mM Ϫ1 . Each mutant showed a reduction in the overall enzyme efficiency by shifting both the K m and the k cat (results are summarized in Table 2 ). Comparison of mutants H65A and C125A reveals a greater effect of the cysteine residue mutation on GilR activity than of the His residue mutation. As expected, the H65A/C125A double mutant shows almost no activity. However, the expressed H65A/ C125A mutant folded appropriately and was still able to bind FAD, although non-covalently (supplemental Fig. S6 ). The N447A mutant decreased the enzyme efficiency by 10-fold, comparable with the H65A mutant but not nearly as great as the approximate 30-fold reduction in activity found upon C125A mutation. The double mutant (H65A/C125A) reduced the enzyme efficiency by greater than 1000-fold, demonstrating a compensatory mechanism between the two residues that cannot be salvaged when both residues are altered.
The three tyrosine residues were also interrogated and the most dramatic reduction in activity from a single mutation was seen with the Y448F mutant. This residue was shown to swing out of the active site to accommodate substrate binding and form a hydrogen bond with the hydroxyl group of the hemiacetal group of preGV. Mutation of this residue alone led to an ϳ400-fold reduction in enzyme efficiency, rendering the remaining activity nearly negligible. Although both Y139F and Y445F showed 10-fold reductions in activity and are likely involved in either the catalytic mechanism or coordination of FAD, our results indicated that Tyr-448 plays the predominant role during catalysis, which is consistent with the proposed hydride ion transfer for flavin-dependent oxidases (35) .
Comparison with Related Proteins-Blast search of GilR revealed its amino acid sequence similarity to a variety of putative oxidoreductases from microbial secondary metabolite pathways such as ChryRM (50% identity/63% similarity) from chrysomycin, RavRM (47%/60%) from ravidomycin, Ken19 (43%/59%) from kendomycin, and BusJ (42%/59%) from spinosyn pathways. The exact functional role of these homologous proteins has not been established yet. AknOx, the well characterized dehydrogenase from aclacinomycin biosynthetic pathway, shares 42% amino acid sequence identity and 58% similarity with GilR. Thus, it was used for molecular replacement to solve the GilR structure. Relatively lower amino acid sequence identity of GilR was also observed for glucose oxidase from Acrimonium strictum (AAS79317, 32.6%), the berberine bridging enzyme from Eschscholzia californica (AAC39358, 27.0%), chito-oligosaccharide oxidase from Fusarium graminearum (XP_391174, 30.0%), and hexose oxidase from Chondrus crispus (AAB49376, 29.0%). Sequence analysis of GilR also revealed conserved domains found in two superfamily enzymes: the FAD_binding_4 superfamily and the berberine bridging enzyme superfamily. Berberine bridging enzyme domain-containing enzymes are involved in the biosynthesis of numerous isoquinoline alkaloids. They catalyze a ring closure reaction in which the N-methyl group of (S)-reticuline is transformed into the C-8 berberine bridge carbon of (S)-scoulerine (36). FAD_binding_4 family enzymes cover a variety of oxidoreductases, including the vanillyl-alcohol oxidases, which catalyze the oxidation of a wide variety of substrates ranging from aromatic amines to 4-alkylphenols. This family of enzymes strictly requires FAD as a co-factor (37) . The sequence alignment of GilR with its closest homologs AknOx, glucose oxidase, berberine bridging enzyme, chito-oligosaccharide oxidase, and hexose oxidase using STRAP (38) and Jalview (39, 40) is depicted in supplemental Fig. S7 . A subsequent DALI search for protein structure comparison yielded the highest matches with the same enzymes. Thus, the alignment shown in supplemental Fig. S7 is based on both sequence and structural homology and, therefore, represents also matches from the DALI server (41) .
To probe enzymes with similar function in addition to similar sequence and structure, we combed the literature for examples of lactone-forming enzymes. Lactone formation through a hemiacetal precursor is relatively uncommon, as discussed by Kharel et al. (17) . Only a few examples of this mechanism have been described, including ascorbic acid biosynthesis with L-galactose dehydrogenase or the pentose phosphate pathway utilizing glucose-6-phosphate dehydrogenase (42, 43) . Both of these reactions use NAD ϩ or NADP ϩ , respectively, as cofactors rather than FAD as was shown for GilR. However, an F 420 -dependent glucose-6-phosphate dehydrogenase (FGD1 or FGD2) from Mycobacterium tuberculosis catalyzes a flavin-dependent hemiacetal to lactone conversion (44) . As the closest related protein with the same function found in the literature, we compared the crystal structures of FGD1 and GilR but found no structural conservation. Although FGD1 is also a homodimer, each monomer forms an (␣/␤) 8 TIM-barrel drastically different from the structure of GilR.
DISCUSSION
Combinatorial biosynthesis has proven to be a successful approach for producing anti-cancer compounds (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) . Lead compounds can be further modified, optimized, and assessed for their efficacy as anti-cancer therapeutics. Our laboratory studies the biosynthetic pathways of selected members of the gilvocarcin group, and three closely related biosynthetic gene clusters (of gilvocarcin V 1, of ravidomycin V 4, and of chrysomycin A 5, supplemental Fig. S1 ) were cloned and characterized (14) . Key steps of this pathway include the oxidative rearrangement cascade and the final dehydrogenation step catalyzed by GilR, which converts a hemiacetal into the central lactone moiety of the polyketide-derived tetracyclic ring skeleton of the gilvocarcins ( Fig. 1 and supplemental Fig. S1 ) (15, 16, 64 -66) . GilR was shown to have very narrow substrate speci- FIGURE 5 . A, the active site of GilR shows GilR in gold tube representation, FAD and active site residues in stick, and important interactions indicated by yellow dashed lines. B, the active site of liganded GilR shows interactions between important catalytic residues in GilR, FAD, and preGV. GilR is shown in gold tube representation, FAD, preGV, and important GilR residues are in stick, and interactions important for catalysis are indicated by black dashed lines. C, shown is a comparison of active site residues for apo (gold) and preGV-bound (green) GilR structures. GilR is shown in green ribbon, and preGV and active site residues are shown in stick representation. The only significant conformational change occurs at Tyr-448 to accommodate the presence of the preGV substrate. FAD has been removed for clarity. D, shown is the proposed mechanism for catalysis in GilR based upon both structural and biochemical analyses.
ficity and does not tolerate alternative molecules with different sugar residues (17) . This narrow substrate specificity is a major obstacle for future approaches to generate better, soluble gilvocarcin analogues with improved biological and pharmacological properties by combinatorial biosynthesis, as targeting the variation of the sugar moiety is the most promising and most feasible strategy. Therefore, to understand the substrate binding and catalysis by GilR and to overcome its narrow substrate specificity, we report here the high resolution crystal structures of GilR in apo form and in complex with its substrate pregilvocarcin V.
Our structural and biochemical analysis has revealed that GilR contains a bicovalently attached FAD cofactor mediated through His-65 and Cys-125. This observation classifies GilR into a small group of a relatively new type of the vanillyl-alcohol-oxidase flavoprotein family characterized by bicovalently tethered cofactors (67) . It is still not entirely clear what role the covalent bonds serve, but it has been shown in related enzymes that the bicovalent attachment increases the redox potential and also may affect the accessibility of the FAD molecule (67) (68) (69) (70) .
GilR was found as a dimer in our crystal structures, and this was further verified by light scattering and analytical ultracentrifugation experiments. The fact that the supernatant of the Y445F mutant also contained abundant FAD indicates that Tyr-445 is somewhat involved in mediating the covalent attachment of FAD to the enzyme. Tyr-445 may be important for the correct enzyme folding at the active site necessary for the formation of the covalent bonds between enzyme and FAD co-factor, and mutation of this residue impedes this process. The biochemical studies also exposed Tyr-448, which swings away from the active site to accommodate binding of the substrate, as an essential residue involved in the initiation of catalysis by forming an important hydrogen bond with the hydroxyl residue of the substrate hemiacetal. The overall arrangement of active site residues of the GilR structure, with the substrate binding between the FAD cofactor and the three tyrosine residues Tyr-448, Tyr-139, and Tyr-445 combined with the amino acid mutations are in agreement with the reaction mechanism shown in Fig. 5D ; that is, Tyr-448 aided by Tyr-139 abstract the proton of the 6-OH group of preGV, with concomitant hydride transfer of 6-H to N-5 of the FAD. The latter process is facilitated by Tyr-445, which protonates the 2-CAO group of FAD, thereby enhancing the electrophilicity of its N5-position. The bicovalently bound FAD co-factor is likely to enforce the correct geometry for this interaction. The reduced flavin then has to be reoxidized by molecular oxygen, thereby forming H 2 O 2 as byproduct. This re-oxidation process has been shown to become the rate-limiting step in the related berberine bridge enzyme (68) . It is clear from the GilR structure that this process can only handle the diastereomer of preGV, in which C-6 is R-configured. PreGV was found as a mixture of diastereomers in which the 6R and the 6S forms are interconvertible through ring opening/closing (17) . Although not experimentally proven, it is likely that only the correct stereoisomer gains access to the active site of GilR from an equilibrium outside, as the interconversion from S-preGV to R-preGV would be obstructed in the enzyme tight active site pocket.
Overall, the structural and initial biochemical studies of GilR not only describe important functional characteristics of this intriguing enzyme but also lay the foundation for broadening the substrate specificity of this bottleneck enzyme for the development of compounds for use as cancer therapeutics. Given the rather constricted binding pocket and the relatively hydrophobic nature of some of the interactions from GilR, it is not surprising that GilR has narrow substrate specificity, particularly with respect to the deoxysugar moiety of the substrate. The mentioned homologs, e.g. AknOx, glucose oxidase, or berberine bridging enzyme, offer only limited help for the planned redesign of the substrate binding site of GilR, as their substrates are so different from pregilvocarcin V. For instance, the aclacinomycin precursor binding to AknOx binds with the end of its rather flexible trisaccharide chain to the active site, because its terminal sugar needs to be oxidized, whereas the tetracyclic aromatic aglycones of aclacinomycin binds far outside the active site (29) . The compact structure of pregilvocarcin V is quite unique in comparison. However, AknOx and some of the other homologs have a more open entrance to the active site, which could help us to design a more open entrance passage for larger (or different) substrates for GilR. There are a number of aromatic residues at the active site of GilR that could be mutated to create space for molecules with larger functional groups, e.g. pregilvocarcins with larger residues at 2, 3, 7, or the 9 position of its tetracyclic polyketide moiety. However, adding even a small additional residue or additional functional group at the five-membered furanose ring may be enough to prevent binding altogether. Therefore, changing the sugar ring into a more common, larger six-membered pyranose will definitely lead to clashes with this narrow binding pocket of GilR and consequently will not allow substrate binding. The Ligplot analysis (supplemental Fig. S5 ) shows two serine residues (Ser-341 and Ser-402) expressing H-bonds to the C-glycosidically bound fucofuranose moiety of preGV. Their mutations (either S341A, S402A, or even S341G or S402G) may open up space for the accommodation of larger six-membered ring sugar moieties.
Other valuable information may be gained from the structures of the corresponding enzymes ChryRM or RavRM, as both chrysomycin A and ravidomycin V contain larger six-membered sugar residues.
